PROMACULA® is a cost-effective treatment
The Cochrane reviews criticise the fact that none of the analysed reviews take account of factors such as quality of life or cost. This gap has now been closed in a cost-benefit analysis from the UK.
AMD patients with advanced AMD (AREDS category 4) have a better quality of life and lower treatment costs compared to those who do not receive any AREDS supplementation. The simulation of 100,000 virtual patients in each study arm (treatment and control group) was based, among others, on the patient data from the ARED study:
The profitability analysis shows:
AREDS supplementation results in a higher quality of life and lower treatment costs.1) With PROMACULA®, not only are you offering your patients the medical gold standard, but also an efficient treatment.
(1) Lee AY, Butt T, Chew E, et al.; Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data, Br J Ophthalmol 2017;0:1-8.